BioCentury
ARTICLE | Clinical News

Alteplase regulatory update

March 11, 2013 7:00 AM UTC

Kyowa and Mitsubishi Tanabe said Japan's Ministry of Health, Labor and Welfare (MHLW) approved the use of Activacin/ GRTPA alteplase within 4.5 hours of the onset of symptoms of acute ischemic cerebrovascular disease. Previously, the tissue plasminogen activator (tPA) was approved to treat acute ischemic cerebrovascular disease within a 3 hour window of onset of symptoms. ...